<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB02699</drugbank-id>
  <drugbank-id>EXPT02464</drugbank-id>
  <name>4-Oxoretinol</name>
  <description/>
  <cas-number>62702-55-0</cas-number>
  <unii/>
  <average-mass>300.4351</average-mass>
  <monoisotopic-mass>300.20893014</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>experimental</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as retinoids. These are oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.</description>
    <direct-parent>Retinoids</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Lipids and lipid-like molecules</superclass>
    <class>Prenol lipids</class>
    <subclass>Retinoids</subclass>
    <alternative-parent>Cyclohexenones</alternative-parent>
    <alternative-parent>Diterpenoids</alternative-parent>
    <alternative-parent>Fatty alcohols</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Primary alcohols</alternative-parent>
    <substituent>Alcohol</substituent>
    <substituent>Aliphatic homomonocyclic compound</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Cyclic ketone</substituent>
    <substituent>Cyclohexenone</substituent>
    <substituent>Diterpenoid</substituent>
    <substituent>Fatty acyl</substituent>
    <substituent>Fatty alcohol</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Ketone</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Primary alcohol</substituent>
    <substituent>Retinoid skeleton</substituent>
  </classification>
  <salts/>
  <synonyms/>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Alkenes</category>
      <mesh-id>D000475</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Carotenoids</category>
      <mesh-id>D002338</mesh-id>
    </category>
    <category>
      <category>Cyclohexanes</category>
      <mesh-id>D003510</mesh-id>
    </category>
    <category>
      <category>Cyclohexenes</category>
      <mesh-id>D053138</mesh-id>
    </category>
    <category>
      <category>Cycloparaffins</category>
      <mesh-id>D003516</mesh-id>
    </category>
    <category>
      <category>Hydrocarbons, Acyclic</category>
      <mesh-id>D006839</mesh-id>
    </category>
    <category>
      <category>Pigments, Biological</category>
      <mesh-id>D010860</mesh-id>
    </category>
    <category>
      <category>Polyenes</category>
      <mesh-id>D011090</mesh-id>
    </category>
    <category>
      <category>Retinoids</category>
      <mesh-id>D012176</mesh-id>
    </category>
    <category>
      <category>Terpenes</category>
      <mesh-id>D013729</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1x8l</pdb-entry>
  </pdb-entries>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>The therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The therapeutic efficacy of Estradiol can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinylestradiol</name>
      <description>The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>The therapeutic efficacy of Mestranol can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>The therapeutic efficacy of Estradiol cypionate can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>The therapeutic efficacy of Estradiol valerate can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00304</drugbank-id>
      <name>Desogestrel</name>
      <description>The therapeutic efficacy of Desogestrel can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>The therapeutic efficacy of Megestrol acetate can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00367</drugbank-id>
      <name>Levonorgestrel</name>
      <description>The therapeutic efficacy of Levonorgestrel can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00717</drugbank-id>
      <name>Norethisterone</name>
      <description>The therapeutic efficacy of Norethisterone can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00823</drugbank-id>
      <name>Ethynodiol diacetate</name>
      <description>The therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00957</drugbank-id>
      <name>Norgestimate</name>
      <description>The therapeutic efficacy of Norgestimate can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>The therapeutic efficacy of Drospirenone can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04839</drugbank-id>
      <name>Cyproterone acetate</name>
      <description>The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06730</drugbank-id>
      <name>Gestodene</name>
      <description>The therapeutic efficacy of Gestodene can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06789</drugbank-id>
      <name>Hydroxyprogesterone caproate</name>
      <description>The therapeutic efficacy of Hydroxyprogesterone caproate can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09123</drugbank-id>
      <name>Dienogest</name>
      <description>The therapeutic efficacy of Dienogest can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09371</drugbank-id>
      <name>Norethynodrel</name>
      <description>The therapeutic efficacy of Norethynodrel can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09389</drugbank-id>
      <name>Norgestrel</name>
      <description>The therapeutic efficacy of Norgestrel can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11619</drugbank-id>
      <name>Gestrinone</name>
      <description>The therapeutic efficacy of Gestrinone can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12474</drugbank-id>
      <name>Lynestrenol</name>
      <description>The therapeutic efficacy of Lynestrenol can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13528</drugbank-id>
      <name>Chlormadinone</name>
      <description>The therapeutic efficacy of Chlormadinone can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13563</drugbank-id>
      <name>Norgestrienone</name>
      <description>The therapeutic efficacy of Norgestrienone can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13685</drugbank-id>
      <name>Quingestanol</name>
      <description>The therapeutic efficacy of Quingestanol can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13857</drugbank-id>
      <name>Demegestone</name>
      <description>The therapeutic efficacy of Demegestone can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13981</drugbank-id>
      <name>Nomegestrol acetate</name>
      <description>The therapeutic efficacy of Nomegestrol acetate can be decreased when used in combination with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00162</drugbank-id>
      <name>Vitamin A</name>
      <description>The risk or severity of adverse effects can be increased when Vitamin A is combined with 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>Valproic acid may increase the Pseudotumor Cerebri activities of 4-Oxoretinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00254</drugbank-id>
      <name>Doxycycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when 4-Oxoretinol is combined with Doxycycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00256</drugbank-id>
      <name>Lymecycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when 4-Oxoretinol is combined with Lymecycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00453</drugbank-id>
      <name>Clomocycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when 4-Oxoretinol is combined with Clomocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00560</drugbank-id>
      <name>Tigecycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when 4-Oxoretinol is combined with Tigecycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00595</drugbank-id>
      <name>Oxytetracycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when 4-Oxoretinol is combined with Oxytetracycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00618</drugbank-id>
      <name>Demeclocycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when 4-Oxoretinol is combined with Demeclocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when 4-Oxoretinol is combined with Tetracycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00931</drugbank-id>
      <name>Metacycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when 4-Oxoretinol is combined with Metacycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01017</drugbank-id>
      <name>Minocycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when 4-Oxoretinol is combined with Minocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01301</drugbank-id>
      <name>Rolitetracycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when 4-Oxoretinol is combined with Rolitetracycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12035</drugbank-id>
      <name>Sarecycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when 4-Oxoretinol is combined with Sarecycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12329</drugbank-id>
      <name>Eravacycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when 4-Oxoretinol is combined with Eravacycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12455</drugbank-id>
      <name>Omadacycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when 4-Oxoretinol is combined with Omadacycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13092</drugbank-id>
      <name>Meclocycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when 4-Oxoretinol is combined with Meclocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13264</drugbank-id>
      <name>Penimepicycline</name>
      <description>The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when 4-Oxoretinol is combined with Penimepicycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The risk or severity of adverse effects can be increased when Methotrexate is combined with 4-Oxoretinol.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>5.31</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.4</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.21e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>4.03</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>3-[(1E,3E,5E,7E)-9-hydroxy-3,7-dimethylnona-1,3,5,7-tetraen-1-yl]-2,4,4-trimethylcyclohex-2-en-1-one</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>4-oxoretinol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>300.4351</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>300.20893014</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)CCC1(C)C</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C20H28O2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C20H28O2/c1-15(7-6-8-16(2)12-14-21)9-10-18-17(3)19(22)11-13-20(18,4)5/h6-10,12,21H,11,13-14H2,1-5H3/b8-6+,10-9+,15-7+,16-12+</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>PLIUCYCUYQIBDZ-RMWYGNQTSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>37.3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>98.62</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>36.69</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>16.44</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-2.2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>44597</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>5289090</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46506951</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C16683</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>4451124</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>OXR</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways>
    <pathway>
      <smpdb-id>SMP0000074</smpdb-id>
      <name>Retinol Metabolism</name>
      <category>metabolic</category>
      <drugs>
        <drug>
          <drugbank-id>DB00157</drugbank-id>
          <name>NADH</name>
        </drug>
        <drug>
          <drugbank-id>DB00162</drugbank-id>
          <name>Vitamin A</name>
        </drug>
        <drug>
          <drugbank-id>DB00523</drugbank-id>
          <name>Alitretinoin</name>
        </drug>
        <drug>
          <drugbank-id>DB00755</drugbank-id>
          <name>Tretinoin</name>
        </drug>
        <drug>
          <drugbank-id>DB01592</drugbank-id>
          <name>Iron</name>
        </drug>
        <drug>
          <drugbank-id>DB01593</drugbank-id>
          <name>Zinc</name>
        </drug>
        <drug>
          <drugbank-id>DB02577</drugbank-id>
          <name>Mesoheme</name>
        </drug>
        <drug>
          <drugbank-id>DB02699</drugbank-id>
          <name>4-Oxoretinol</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P07327</uniprot-id>
        <uniprot-id>Q96NR8</uniprot-id>
        <uniprot-id>Q9BTZ2</uniprot-id>
        <uniprot-id>O75452</uniprot-id>
        <uniprot-id>Q9NYR8</uniprot-id>
        <uniprot-id>O75911</uniprot-id>
        <uniprot-id>Q9BPW9</uniprot-id>
        <uniprot-id>Q8TC12</uniprot-id>
        <uniprot-id>O95237</uniprot-id>
        <uniprot-id>Q58HT5</uniprot-id>
        <uniprot-id>O75907</uniprot-id>
        <uniprot-id>Q16518</uniprot-id>
        <uniprot-id>P41247</uniprot-id>
        <uniprot-id>Q9HAY6</uniprot-id>
        <uniprot-id>P00352</uniprot-id>
        <uniprot-id>O94788</uniprot-id>
        <uniprot-id>O43174</uniprot-id>
        <uniprot-id>Q6NUM9</uniprot-id>
        <uniprot-id>Q9UBS4</uniprot-id>
        <uniprot-id>Q96GW1</uniprot-id>
        <uniprot-id>P11021</uniprot-id>
        <uniprot-id>Q6IN67</uniprot-id>
        <uniprot-id>Q13087</uniprot-id>
        <uniprot-id>P13667</uniprot-id>
        <uniprot-id>Q15084</uniprot-id>
        <uniprot-id>P23284</uniprot-id>
        <uniprot-id>Q9HCN8</uniprot-id>
        <uniprot-id>P22309</uniprot-id>
        <uniprot-id>P30040</uniprot-id>
        <uniprot-id>P11509</uniprot-id>
        <uniprot-id>P20853</uniprot-id>
        <uniprot-id>Q16696</uniprot-id>
        <uniprot-id>P20813</uniprot-id>
        <uniprot-id>P24462</uniprot-id>
        <uniprot-id>P08684</uniprot-id>
        <uniprot-id>P20815</uniprot-id>
        <uniprot-id>Q9HB55</uniprot-id>
      </enzymes>
    </pathway>
    <pathway>
      <smpdb-id>SMP0000336</smpdb-id>
      <name>Vitamin A Deficiency</name>
      <category>disease</category>
      <drugs>
        <drug>
          <drugbank-id>DB00157</drugbank-id>
          <name>NADH</name>
        </drug>
        <drug>
          <drugbank-id>DB00162</drugbank-id>
          <name>Vitamin A</name>
        </drug>
        <drug>
          <drugbank-id>DB00523</drugbank-id>
          <name>Alitretinoin</name>
        </drug>
        <drug>
          <drugbank-id>DB00755</drugbank-id>
          <name>Tretinoin</name>
        </drug>
        <drug>
          <drugbank-id>DB01592</drugbank-id>
          <name>Iron</name>
        </drug>
        <drug>
          <drugbank-id>DB01593</drugbank-id>
          <name>Zinc</name>
        </drug>
        <drug>
          <drugbank-id>DB02577</drugbank-id>
          <name>Mesoheme</name>
        </drug>
        <drug>
          <drugbank-id>DB02699</drugbank-id>
          <name>4-Oxoretinol</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P07327</uniprot-id>
        <uniprot-id>Q96NR8</uniprot-id>
        <uniprot-id>Q9BTZ2</uniprot-id>
        <uniprot-id>O75452</uniprot-id>
        <uniprot-id>Q9NYR8</uniprot-id>
        <uniprot-id>O75911</uniprot-id>
        <uniprot-id>Q9BPW9</uniprot-id>
        <uniprot-id>Q8TC12</uniprot-id>
        <uniprot-id>O95237</uniprot-id>
        <uniprot-id>Q58HT5</uniprot-id>
        <uniprot-id>O75907</uniprot-id>
        <uniprot-id>Q16518</uniprot-id>
        <uniprot-id>P41247</uniprot-id>
        <uniprot-id>Q9HAY6</uniprot-id>
        <uniprot-id>P00352</uniprot-id>
        <uniprot-id>O94788</uniprot-id>
        <uniprot-id>O43174</uniprot-id>
        <uniprot-id>Q6NUM9</uniprot-id>
        <uniprot-id>Q9UBS4</uniprot-id>
        <uniprot-id>Q96GW1</uniprot-id>
        <uniprot-id>P11021</uniprot-id>
        <uniprot-id>Q6IN67</uniprot-id>
        <uniprot-id>Q13087</uniprot-id>
        <uniprot-id>P13667</uniprot-id>
        <uniprot-id>Q15084</uniprot-id>
        <uniprot-id>P23284</uniprot-id>
        <uniprot-id>Q9HCN8</uniprot-id>
        <uniprot-id>P22309</uniprot-id>
        <uniprot-id>P30040</uniprot-id>
        <uniprot-id>P11509</uniprot-id>
        <uniprot-id>P20853</uniprot-id>
        <uniprot-id>Q16696</uniprot-id>
        <uniprot-id>P20813</uniprot-id>
        <uniprot-id>P24462</uniprot-id>
        <uniprot-id>P08684</uniprot-id>
        <uniprot-id>P20815</uniprot-id>
        <uniprot-id>Q9HB55</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>